top of page

Research

Primo piano del microscopio

Our Path to 
Effective Treatments

Research into SLC6A1-related neurodevelopmental disorder (SLC6A1-NDD) is advancing across several complementary areas.

​

From understanding the biological mechanisms of the disorder to developing new therapeutic approaches and preparing for clinical trials, each area contributes to the broader goal of improving treatment options for people affected by SLC6A1-NDD.

Key Areas of Research

Different scientific approaches are progressing in parallel. Together, they build the path toward effective treatments. 

Disease-Modifying Approaches

Research is exploring therapeutic strategies designed to address the underlying biological causes of SLC6A1-NDD.

  • Gene Therapy

  • Antisense Oligonucleotides (ASOs)

  • Other genetic and molecular approaches

New Drugs &
Drug Repurposing

Researchers are investigating both new therapeutic compounds and existing medicines that may have potential benefits for people with SLC6A1-NDD.

  • New Drug Development

  • Drug Repurposing

Preparing for Clinical Trials

Clinical trials require reliable data and tools to measure whether a treatment is safe and effective. Important areas of work include:

  • Outcome measures

  • Biomarkers

  • Natural History Studies

  • Clinical Trial Readiness

Understanding the Biology of
SLC6A1-NDD

Basic and translational research helps scientists better understand how changes in SLC6A1 affect cells, brain function and development. This includes:

  • Disease Mechanisms

  • Cellular Models

  • Animal Models

  • Translational Research

Moving Research Forward

There is unlikely to be a single research approach that answers every need.

Progress will depend on continued collaboration between researchers, clinicians, families, patient organisations and industry, while advancing different therapeutic approaches and improving our understanding of SLC6A1-NDD.

​

Our role at SLC6A1 Europe is to help connect these efforts, support collaboration and contribute to the conditions needed for research to move towards meaningful treatments for people and families affected by SLC6A1-NDD.

bottom of page